TDC

TDC Protein

Score: 0.304 Price: $0.30 Low Druggability Status: active
HYPOTHESES
1
PAPERS
6
KG EDGES
0
DEBATES
1

3D Protein Structure

🔮 TDC — AlphaFold P20711 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Druggability & Clinical Context

Druggability
Low
Score: 0.26
Clinical Stage
Approved
Target Class
Protein
Safety
0.50
Druggability Analysis
Drug Development0.60
Structural Tractability0.30
Target Class0.50
Safety Profile0.50
Key Metrics
PDB Structures:
0
Known Drugs:
1
Approved:
0
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Preclinical
Mechanism: Prioritized from 1 SciDEX hypotheses, including: Restoring Neuroprotective Tryptophan Metabolism via Targeted Probiotic Engineering
Drug Pipeline (1 compounds)
1 Preclinical
Known Drugs:
CHEMBL3228258 (preclinical)
Structural Data:
PDB —AlphaFold ✓Cryo-EM —
UniProt: P20711

🔮 Predicted Protein Structure (AlphaFold)

🔮 TDC — AlphaFold P20711 Click to expand interactive 3D viewer

AI-predicted structure from AlphaFold EBI | Powered by Mol* | Rotate: click+drag | Zoom: scroll

3D Protein Structure (AlphaFold)

Open full viewer

AlphaFold predicted structure available for P20711

View AlphaFold Structure

Clinical Trials (3)

Relevant trials from ClinicalTrials.gov

Active
0
Completed
3
Total Enrollment
184
By Phase
PHASE2: 1 · PHASE4: 2
OpicApone Sleep dISorder Completed
PHASE4 NCT04986995 n=22
Parkinson Disease
Interventions: Opicapone
Sponsor: Bial - Portela C S.A. | Started: 2021-06-09
OpiCapone Effect on Motor Fluctuations and pAiN Completed
PHASE4 NCT04986982 n=144
Parkinson Disease
Interventions: Opicapone 50 mg, Placebo
Sponsor: Bial - Portela C S.A. | Started: 2021-02-25
Mucuna Pruriens Therapy in Parkinson's Disease Completed
PHASE2 NCT02680977 n=18
Parkinson's Disease
Interventions: MP-Equivalent, MP-Low, MP+DDCI
Sponsor: ASST Gaetano Pini-CTO | Started: 2016-02

Linked Hypotheses (1)

Restoring Neuroprotective Tryptophan Metabolism via Targeted Probiotic Engineering0.612

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Portfolio 0.00 (25%) Druggability 0.26 (20%) Evidence 0.54 (20%) Safety 0.50 (15%) Competitive 0.70 (10%) Connectivity 0.00 (10%) 0.304 composite

Knowledge Graph (20)

associated with (3)

TDCneurodegenerationAADCTDCTDCEPHA10

causes (2)

IDO1TDCTDCneuroinflammation

co discussed (7)

TDCTLR4TDCGPR109ATDCAADCTDCDDCTDCCHRNA7
▸ Show 2 more
TDCAGERTDCCSGA

co mentioned (2)

neuroinflammationTDCAADCTDC

debate co mention (5)

CSGATDCGPR109ATDCneuroinflammationTDCTDCTLR4DDCTDC

participates in (1)

TDCinsulin signaling

Debate History (1)

Should TDC (TDC Protein) be prioritized as a therapeutic target for neurodegener2026-04-26